Cambridge, MA's Catabasis Pharmaceuticals has landed a $32.4 million Series B to advance its triglyceride-fighting drug, setting sights on a swelling market with a compound the company believes can outperform its competitors.
Waltham, MA-based GeNO is looking to raise $50 million to back its work on a new, patient-friendly approach for delivering inhaled nitric oxide on the go. And a Dutch biotech, uniQure, is also positioning itself to go public after pioneering the world's first approved gene therapy.
Liquidia Technologies has spun out a new biotech company in Research Triangle Park, NC, which boasts an early-stage ophthalmology program and $25 million in venture backing from some high-profile investors.
Back in September, when Ultragenyx CEO Emil Kakkis was talking to FierceBiotech about the company for our annual Fierce 15 report, the biotech chief confidently predicted that he could take the company public next year.
San Diego-based Sangart has gone missing in action after apparently burning through more than a quarter-billion dollars of Leucadia National cash.
ImmunGene is working to get its lead armed-antibody cancer treatment from the lab to the clinic, and now the California company has $9 million in Series A cash to light the way.
A pair of prominent pharma players are partnering up with a few marquee European VCs to back an up-and-coming immunotherapy biotech based in Vienna.
As biotech venture funding plods along at a middling pace, A-list investor OrbiMed has bagged $735 million for its 5th fund, cash earmarked for life sciences companies across all stages of development.
Biopharma backer NovaQuest has closed a $459 million fund, cash the company will use to push promising, late-stage projects toward commercialization.
Fidelity Biosciences is placing a big bet on gene therapy, funding the launch of startup Dimension Therapeutics with some licensed patents and a plan to develop novel treatments for hemophilia.